ATE432265T1 - Pyrimidinon verbindungen - Google Patents

Pyrimidinon verbindungen

Info

Publication number
ATE432265T1
ATE432265T1 AT04077397T AT04077397T ATE432265T1 AT E432265 T1 ATE432265 T1 AT E432265T1 AT 04077397 T AT04077397 T AT 04077397T AT 04077397 T AT04077397 T AT 04077397T AT E432265 T1 ATE432265 T1 AT E432265T1
Authority
AT
Austria
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AT04077397T
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE432265T1 publication Critical patent/ATE432265T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04077397T 1999-05-01 2000-04-25 Pyrimidinon verbindungen ATE432265T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds

Publications (1)

Publication Number Publication Date
ATE432265T1 true ATE432265T1 (de) 2009-06-15

Family

ID=26243514

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00920741T ATE283845T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen
AT04077397T ATE432265T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00920741T ATE283845T1 (de) 1999-05-01 2000-04-25 Pyrimidinon verbindungen

Country Status (29)

Country Link
US (2) US6953803B1 (de)
EP (2) EP1479671B1 (de)
JP (1) JP2002543190A (de)
KR (1) KR20020012200A (de)
CN (1) CN1286822C (de)
AR (1) AR023777A1 (de)
AT (2) ATE283845T1 (de)
AU (1) AU766003B2 (de)
BR (1) BR0010220A (de)
CA (1) CA2371671A1 (de)
CO (1) CO5170521A1 (de)
CZ (1) CZ20013904A3 (de)
DE (2) DE60042286D1 (de)
DK (1) DK1175408T3 (de)
ES (1) ES2233361T3 (de)
HK (1) HK1044757B (de)
HU (1) HUP0201122A3 (de)
IL (1) IL146210A0 (de)
MX (1) MXPA01011186A (de)
MY (1) MY136037A (de)
NO (1) NO20015329L (de)
NZ (1) NZ515137A (de)
PE (1) PE20010070A1 (de)
PL (1) PL351690A1 (de)
PT (1) PT1175408E (de)
SI (1) SI1175408T1 (de)
TR (1) TR200103216T2 (de)
UY (1) UY26132A1 (de)
WO (1) WO2000066567A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042286D1 (de) * 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
DE60139429D1 (de) 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) * 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
TW201209043A (en) 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
US8637536B2 (en) * 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
AU2012335220B2 (en) * 2011-11-11 2017-06-01 Pfizer Inc. 2-thiopyrimidinones
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Lp‐PLA2の阻害剤としての二環式ピリミドン化合物
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维(上海)医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
JP2026516205A (ja) 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Lp-pla2阻害剤と第2の薬剤の併用治療
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
WO1999024420A1 (en) * 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
DE60042286D1 (de) * 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen

Also Published As

Publication number Publication date
HUP0201122A2 (en) 2002-08-28
US20040167142A1 (en) 2004-08-26
WO2000066567A1 (en) 2000-11-09
PT1175408E (pt) 2005-04-29
EP1175408A1 (de) 2002-01-30
CA2371671A1 (en) 2000-11-09
US7115616B2 (en) 2006-10-03
HUP0201122A3 (en) 2003-11-28
MY136037A (en) 2008-08-29
EP1479671A1 (de) 2004-11-24
ATE283845T1 (de) 2004-12-15
TR200103216T2 (tr) 2002-04-22
PL351690A1 (en) 2003-06-02
EP1175408B1 (de) 2004-12-01
AU4120300A (en) 2000-11-17
IL146210A0 (en) 2002-07-25
HK1044757B (en) 2005-07-08
AU766003B2 (en) 2003-10-09
MXPA01011186A (es) 2002-08-12
EP1479671B1 (de) 2009-05-27
DE60016397D1 (de) 2005-01-05
UY26132A1 (es) 2000-12-29
NZ515137A (en) 2003-10-31
DE60016397T2 (de) 2005-12-01
PE20010070A1 (es) 2001-03-10
JP2002543190A (ja) 2002-12-17
HK1044757A1 (en) 2002-11-01
ES2233361T3 (es) 2005-06-16
CZ20013904A3 (cs) 2002-04-17
NO20015329D0 (no) 2001-10-31
CN1358175A (zh) 2002-07-10
DK1175408T3 (da) 2005-04-11
US6953803B1 (en) 2005-10-11
AR023777A1 (es) 2002-09-04
DE60042286D1 (de) 2009-07-09
SI1175408T1 (en) 2005-04-30
BR0010220A (pt) 2002-05-14
CO5170521A1 (es) 2002-06-27
NO20015329L (no) 2001-10-31
CN1286822C (zh) 2006-11-29
KR20020012200A (ko) 2002-02-15

Similar Documents

Publication Publication Date Title
DE60042286D1 (de) Pyrimidinon Verbindungen
DE60031682D1 (de) Antibakterielle verbindungen
CY2015035I2 (el) Ενωσεις πυριμιδινης
EE200100502A (et) Ühendid
NO20024127L (no) Pyrimidin-forbindelser
NO20015536L (no) FAP-aktiverte anti-tumor-forbindelser
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
ATE283049T1 (de) Antibakterielle verbindungen
DE69807397D1 (de) Triazinylaminostilben Verbindungen
NO20021503D0 (no) Kinazolinoner
DE69939378D1 (de) Antithrombotische verbindungen
NO20014926D0 (no) Farmasöytiske forbindelser
ATE258921T1 (de) Aryl-annellierte azapolycyclische verbindungen
MXPA01011760A (es) Compuestos novedosos de difeniletileno.
ID29533A (id) Senyawa-senyawa kalsilitik
NO20021502D0 (no) Kinazolinoner
DE60132607D1 (de) Bicyclische heteroaromatische verbindungen
NO20020466L (no) Kalsilytiske forbindelser
DE60035826D1 (de) Entfernungsmesser
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
NO20014262D0 (no) Tiazoloindolinon-forbindelser
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
SE9902903D0 (sv) Novel compounds
SE9903080D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties